Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose

Tyrosine kinase inhibitors (TKIs) are anti‐cancer drugs that target tyrosine kinases, enzymes that are involved in multiple cellular processes. Currently, multiple oral TKIs have been introduced in the treatment of solid tumours, all administered in a fixed dose, although large interpatient pharmaco...

Descripción completa

Detalles Bibliográficos
Autores principales: Westerdijk, Kim, Desar, Ingrid M.E., Steeghs, Neeltje, van der Graaf, Winette T.A., van Erp, Nielka P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7015742/
https://www.ncbi.nlm.nih.gov/pubmed/31782166
http://dx.doi.org/10.1111/bcp.14185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7015742/
https://www.ncbi.nlm.nih.gov/pubmed/31782166
http://dx.doi.org/10.1111/bcp.14185

Ejemplares similares